Effects of intestinal and graft liver CYP2C19 genotypes on the C/D ratio of tacrolimus coadministered with omeprazole (n = 35) or lansoprazole (n = 54)
Data are expressed as median (range). CYP3A5*1 noncarriers, CYP3A5*3/*3. P values are for the differences among the genotype groups, using the Kruskal-Wallis test, followed by the Dunn post hoc test for multiple comparisons.
PPI | Variables | CYP2C19 Genotype (CYP3A5*1 Noncarriers) | P | ||||
|---|---|---|---|---|---|---|---|
| EMs | IMs | PMs | |||||
| Omeprazole | Native intestine | ||||||
| n | 11 (9) | 15 (9) | 9 (9) | ||||
| Tacrolimus C/D ratio | 2.11 (1.04-2.54) | 2.11 (0.52-4.33) | 6.38*† (1.55-22.9) | 0.010 | |||
| Graft liver | |||||||
| n | 10 (6) | 13 (8) | 12 (7) | ||||
| Tacrolimus C/D ratio | 1.83 (1.04-6.38) | 2.31 (0.52-7.10) | 3.27* (1.9-22.9) | 0.022 | |||
| Lansoprazole | Native intestine | ||||||
| n | 16 (11) | 27 (21) | 11 (4) | ||||
| Tacrolimus C/D ratio | 2.34 (1.16-12.8) | 2.83 (0.72-13.4) | 2.27 (0.98-11.7) | 0.52 | |||
| Graft liver | |||||||
| n | 15 (9) | 30 (22) | 9 (7) | ||||
|
| Tacrolimus C/D ratio | 2.47 (1.13-10.6) | 2.76 (1.10-12.8) | 2.20 (0.72-13.4) | 0.82 | ||
↵* P < 0.05, EMs versus PMs; †P < 0.05, IMs versus PMs.